Table 3.
Subgroup analysis of PFS and OS.
| Items | PFS | OS | ||||
|---|---|---|---|---|---|---|
| Median PFS (95% CI), months | HR (95% CI) | P-value | 1-year OS rate, (%)* | HR (95% CI) | P-value | |
| Age | 0.473 | 0.848 | ||||
| ≤65 years | 10.0 (7.3–12.6) | 1.000 | 65.4 | 1.000 | ||
| >65 years | 9.0 (4.5–13.5) | 1.393 (0.563–3.445) | 48.5 | 1.116 (0.365–3.409) | ||
| Gender | 0.832 | 0.856 | ||||
| Female | incalculable | 1.000 | 71.4 | 1.000 | ||
| Male | 9.7 (7.4–12.0) | 0.878 (0.264–2.924) | 61.0 | 0.873 (0.200–3.805) | ||
| HBV | 0.220 | 0.290 | ||||
| No | 18.0 (incalculable) | 1.000 | 88.9 | 1.000 | ||
| Yes | 9.2 (5.9–12.5) | 2.113 (0.639–6.992) | 58.2 | 2.976 (0.395–22.402) | ||
| ECOG PS score | 0.926 (0.474–1.810)# | 0.822 | 1.223 (0.501–2.984)# | 0.659 | ||
| 0 | 7.3 (3.0–11.6) | – | 63.8 | – | ||
| 1 | 10.0 (7.7–12.2) | – | 61.8 | – | ||
| 2 | incalculable | – | incalculable | – | ||
| Child–Pugh class | 0.118 | 0.605 | ||||
| A | 9.0 (5.7–12.3) | 1.000 | 56.9 | 1.000 | ||
| B | 18.0 (6.0–30.0) | 0.488 (0.199–1.199) | 74.7 | 0.745 (0.244–2.271) | ||
| Extrahepatic metastasis | 0.509 | 0.143 | ||||
| No | 11.0 (4.7–17.3) | 1.000 | 68.8 | 1.000 | ||
| Yes | 9.2 (5.3–13.2) | 1.265 (0.630–2.537) | 58.0 | 2.093 (0.778–5.628) | ||
| Vascular invasion | 0.170 | 0.007 | ||||
| No | 11.0 (8.2–13.8) | 1.000 | 76.3 | 1.000 | ||
| Yes | 6.2 (4.4–8.0) | 1.627 (0.811–3.263) | 43.7 | 4.152 (1.476–11.680) | ||
| BCLC stage | 0.685 | 0.138 | ||||
| B | 9.7 (7.0–12.4) | 1.000 | 74.7 | 1.000 | ||
| C | 10.0 (4.4–15.5) | 1.174 (0.540–2.553) | 56.7 | 2.563 (0.739–8.887) | ||
| CNLC stage | 1.220 (0.832–1.790)# | 0.308 | 1.852 (0.960–3.569)# | 0.066 | ||
| Ib | incalculable | – | incalculable | – | ||
| IIa | 11.0 (incalculable) | – | incalculable | – | ||
| IIb | 9.7 (6.2–13.2) | – | 80.0 | – | ||
| IIIa | 11.8 (0.5–23.0) | – | 49.8 | – | ||
| IIIb | 9.2 (5.2–13.2) | – | 59.6 | – | ||
| AFP | 0.255 | 0.090 | ||||
| <400 ng/ml | 9.0 (5.5–12.5) | 1.000 | 71.5 | 1.000 | ||
| ≥400 ng/ml | 11.4 (8.7–14.1) | 0.639 (0.295–1.383) | 51.8 | 2.308 (0.876–6.080) | ||
| UK | – | – | – | – | ||
| Hepatectomy | 0.631 | 0.587 | ||||
| No | 9.7 (4.9–14.5) | 1.000 | 59.5 | 1.000 | ||
| Yes | 9.0 (2.9–15.1) | 0.823 (0.371–1.826) | 73.6 | 0.709 (0.205–2.451) | ||
| Times of previous TACE | 0.963 (0.722–1.286)# | 0.800 | 1.537 (1.100–2.149)# | 0.012 | ||
| 0 | 9.7 (5.8–13.6) | – | 87.8 | – | ||
| 1 | 11.4 (5.9–16.9) | – | 59.3 | – | ||
| 2 | 9.2 (3.0–15.5) | – | 67.3 | – | ||
| 3 | 5.1 (incalculable) | – | 62.5 | – | ||
| >3 | 9.0 (0.0–19.0) | – | 24.3 | – | ||
| Previous treatment lines | 0.675 (0.302–1.511)# | 0.339 | 1.512 (0.656–3.482)# | 0.332 | ||
| First-line | 9.7 (5.7–13.6) | – | 63.9 | – | ||
| Second-line | 10.0 (2.4–17.5) | – | 42.1 | – | ||
| >Second-line | incalculable | – | incalculable | – | ||
| Times of TACE, No. (%) | 0.111 | 0.095 | ||||
| ≤3 | 9.7 (5.5–13.9) | 1.000 | 61.0 | 1.000 | ||
| >3 | 11.0 (7.7–14.3) | 0.479 (0.193–1.185) | 77.8 | 0.281 (0.063–1.245) | ||
| Timing of camrelizumab administration, No. (%) | 0.222 | 0.159 | ||||
| Before TACE | 10.0 (incalculable) | 1.000 | 60.0 | 1.000 | ||
| After TACE | 9.2 (5.1–13.3) | 3.491 (0.470–25.920) | 62.4 | 0.345 (0.078–1.515) | ||
| Treatment cycle of camrelizumab | 0.763 | 0.551 | ||||
| Q2W | 9.0 (incalculable) | 1.000 | incalculable | 1.000 | ||
| Q3W | 9.7 (5.7–13.6) | 0.801 (0.189–3.389) | 60.4 | 21.574 (0.001–517,391.446) | ||
| Cycles of camrelizumab, No. (%) | 0.503 (0.320–0.792) # | 0.003 | 0.401 (0.221–0.729) # | 0.003 | ||
| ≤2 | 6.5 (1.6–11.5) | – | 60.0 | – | ||
| 3–4 | 3.9 (2.1–5.8) | – | 19.1 | – | ||
| >4 | 11.4 (10.5–12.3) | – | 82.4 | – | ||
| Interval between TACE and camrelizumab administration | 1.702 (1.039–2.790)# | 0.035 | 2.542 (1.398–4.620)# | 0.002 | ||
| Within 7 days | 11.0 (9.0–13.0) | – | 67.5 | – | ||
| Within 8 to 14 days | 6.7 (incalculable) | – | 66.7 | – | ||
| Within 15 to 28 days | 4.2 (3.7–4.7) | – | 0.0 | – | ||
| Treatment regimen | 0.824 | 0.460 | ||||
| Monotherapy of camrelizumab | 10.0 (3.6–16.3) | 1.000 | 58.6 | 1.000 | ||
| Combination therapy with TKI | 9.7 (7.1–12.3) | 1.082 (0.539–2.171) | 64.0 | 0.704 (0.277–1.787) | ||
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; ECOG PS, Eastern Cooperative Oncology Group Performance Status; BCLC, Barcelona Clinic Liver Cancer; CNLC, China liver cancer; AFP, alpha-fetoprotein; UK, unknown; TACE, transarterial chemoembolization; Q2W, every 2 weeks; Q3W, every 3 weeks; TKI, tyrosine kinase inhibitors.
*Median OS was incalculable, thus 1-year OS rate was used; #The variables were regarded as ordinal categorical variables instead of polytomous variable. The bold values indicate the comparison with statistical significance.